MSB 1.05% 96.0¢ mesoblast limited

Ann: Submits New Information to FDA IND File for SR-aGVHD, page-15

  1. 2,033 Posts.
    lightbulb Created with Sketch. 317
    "but always deliver on what they say they will do"
    I had to laugh at that one thanks. Maybe the ledger is upside down or you are dyslexic?

    From May2019
    Mesoblast Chief Executive Dr Silviu Itescu stated: “Initiation of our rolling BLA submission to the FDA for potential United States approval of our first product is a major corporate milestone for the Company and an exciting moment in our history. We look forward to making this therapy available assoon as possible to children with this devastating disease.”

    Jan2020
    If approved, remestemcel-L is planned to be launched in the US in 2020.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
96.0¢
Change
0.010(1.05%)
Mkt cap ! $1.096B
Open High Low Value Volume
94.5¢ 97.5¢ 94.0¢ $2.076M 2.161M

Buyers (Bids)

No. Vol. Price($)
4 162826 96.0¢
 

Sellers (Offers)

Price($) Vol. No.
97.0¢ 28820 3
View Market Depth
Last trade - 16.10pm 21/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.